Showing results (511-520 of 578) with videos related to

Sort By:
Pageof 58
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2022
Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine TumorsClare Vesely, Yien Ning Sophia Wong, Alexa Childs, et al.
British Journal of Cancer|January 15, 2019
Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumoursFrancesca M Rizzo, Clare Vesely, Alexa Childs, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|August 5, 2014
Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within Milan criteriaIoanna Parisi, Emmanuel Tsochatzis, Hasitha Wijewantha, et al.
JHEP Reports : Innovation in Hepatology|January 16, 2026
Fine needle aspirates characterise the hepatocellular carcinoma immune niche to predict immune checkpoint inhibitor outcomesGloryanne Aidoo-Micah, Stephanie Kucykowicz, Nathalie Schmidt, et al.
Liver Cancer|February 28, 2022
Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular CarcinomaLorenza Rimassa, Robin Kate Kelley, Tim Meyer, et al.
World Journal of Gastroenterology|October 30, 2019
Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centresMelissa Frizziero, Xin Wang, Bipasha Chakrabarty, et al.
BMJ Open|February 8, 2020
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)Zoe Craig, Jayne Swain, Emma Batman, et al.
British Journal of Cancer|January 27, 2017
Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasionImam Waked, Sarah Berhane, Hidenori Toyoda, et al.
Nature Reviews. Clinical Oncology|June 10, 2026
Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statementJosep M Llovet, Ezequiel Mauro, Lorenza Rimassa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2020
Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular CarcinomaRobin Kate Kelley, Tim Meyer, Lorenza Rimassa, et al.
Pageof 58